– USA, MA – Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Edward (Ted) Myles, a financial and operational leader with deep experience across the biotechnology and pharmaceutical industries, has been appointed to the Company’s Board of Directors. Mr. Myles will serve as chair of the Company’s audit committee and as a member of the compensation committee.
“We are very pleased to welcome Ted to Scholar Rock’s Board of Directors as we further enhance the breadth of industry expertise of the Board,” said David Hallal, Chairman of the Board. “Ted brings more than 20 years of experience and insights into building operational functions and developing financial strategies at every stage, from early discovery to commercial stage companies, which will be invaluable to the Board and management as Scholar Rock progresses its robust, highly innovative pipeline and continues to successfully grow as a public company.”
About Ted Myles
Since 2016, Mr. Myles has served as Executive Vice President and Chief Financial Officer of AMAG Pharmaceuticals, Inc. Prior to joining AMAG, he served as Chief Financial Officer and Chief Operating Officer at Ocata Therapeutics, Inc. before its acquisition by Astellas Pharma, Inc. His prior leadership positions include Chief Financial Officer and Vice President of Operations at PrimeraDx, Inc. and Controller of EMD Pharmaceuticals (now EMD Serono, a part of Merck KGaA). Earlier in his career, Mr. Myles was an associate in the healthcare investment banking group at SG Cowen Securities Corporation and was a senior associate in the audit practice of Coopers & Lybrand LLP. Mr. Myles holds a Master of Business Administration from John M. Olin School of Business at Washington University and Bachelor of Science in Business Administration from the University of Hartford.
“I am honored to be joining the Scholar Rock Board and to be part of such a dynamic team,” said Mr. Myles. “This is an exciting and transformative time for Scholar Rock and I look forward to applying my financial expertise and deep industry knowledge to support the continued execution of the Company’s strategy and advancement of a broad pipeline of novel product candidates focused on addressing neuromuscular disorders, cancer, fibrosis, and anemia.”
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock’s newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
For more information : http://www.ScholarRock.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
